CL2015003266A1 - Formulación estabilizada de pemetrexed. - Google Patents

Formulación estabilizada de pemetrexed.

Info

Publication number
CL2015003266A1
CL2015003266A1 CL2015003266A CL2015003266A CL2015003266A1 CL 2015003266 A1 CL2015003266 A1 CL 2015003266A1 CL 2015003266 A CL2015003266 A CL 2015003266A CL 2015003266 A CL2015003266 A CL 2015003266A CL 2015003266 A1 CL2015003266 A1 CL 2015003266A1
Authority
CL
Chile
Prior art keywords
pemetrexed
formulation
stabilized formulation
air space
container
Prior art date
Application number
CL2015003266A
Other languages
English (en)
Inventor
Young Joon Park
Myung Jin Shin
Hong Chul Jin
Ha Yong Choi
Nak Hyun Choi
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of CL2015003266A1 publication Critical patent/CL2015003266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

UNA FORMULACION QUE COMPRENDE PEMETREXED O UNA SAL DEL MISMO COMO PRINCIPIO ACTIVO, N-ACETIL-L-CISTEINA Y CITRATO SODICO; Y FORMULACION DE PEMETREXED CARGADA EN UN RECIPIENTE SELLADO QUE COMPRENDE UN CONTENIDO DE GAS OXIGENO DEL 3% V/V O MENOR DENTRO DEL ESPACIO AEREO DEL RECIPIENTE, RESPECTO DEL VOLUMEN TOTAL DEL ESPACIO AEREO.
CL2015003266A 2013-05-08 2015-11-06 Formulación estabilizada de pemetrexed. CL2015003266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130052083A KR101485243B1 (ko) 2013-05-08 2013-05-08 안정화된 페메트렉시드 제제

Publications (1)

Publication Number Publication Date
CL2015003266A1 true CL2015003266A1 (es) 2016-04-22

Family

ID=51867494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003266A CL2015003266A1 (es) 2013-05-08 2015-11-06 Formulación estabilizada de pemetrexed.

Country Status (13)

Country Link
US (1) US9629844B2 (es)
EP (1) EP2995298B1 (es)
JP (1) JP6159879B2 (es)
KR (1) KR101485243B1 (es)
CN (1) CN105451717B (es)
BR (1) BR112015028124B1 (es)
CL (1) CL2015003266A1 (es)
ES (1) ES2890523T3 (es)
HK (1) HK1218076A1 (es)
MX (1) MX362807B (es)
PH (1) PH12015502542A1 (es)
RU (1) RU2636783C2 (es)
WO (1) WO2014182093A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
WO2016082714A1 (zh) * 2014-11-26 2016-06-02 台湾东洋药品工业股份有限公司 具有长期稳定性的不含抗氧化剂的药物注射溶液的制备方法
US10869867B2 (en) 2015-02-13 2020-12-22 Sun Pharmaceutical Industries Ltd. Intravenous infusion dosage form
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
US10369077B2 (en) * 2017-05-31 2019-08-06 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using the same
WO2019043569A1 (en) * 2017-08-29 2019-03-07 Fresenius Kabi Oncology Limited STREAMABLE LIQUID COMPOSITIONS OF PEMETREXED
KR20220130253A (ko) * 2018-11-14 2022-09-26 에이브이엠 바이오테크놀로지, 엘엘씨 안정한 글루코코르티코이드 제제
WO2021192471A1 (ja) * 2020-03-24 2021-09-30 ナガセ医薬品株式会社 ペメトレキセド製剤
WO2023237093A1 (zh) * 2022-06-09 2023-12-14 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
KR20020081293A (ko) * 2000-02-04 2002-10-26 일라이 릴리 앤드 캄파니 페메트렉시드를 모노티오글리세롤 ｌ-시스테인 또는티오글리콜산과 함께 포함하는 제약 조성물
CZ303772B6 (cs) 2000-02-25 2013-05-02 Eli Lilly And Company Heptahydrátová krystalická forma disodné soli N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]L-glutamové kyseliny a zpusob její prípravy
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
ES2336034T3 (es) 2004-03-10 2010-04-07 Shimoda Biotech (Pty) Ltd Composiciones de diclofenaco inyectables estables.
EP2072518A1 (en) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR101069128B1 (ko) 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
SI2854768T1 (sl) * 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Farmacevtski sestavki pemetrekseda
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
PH12015502542B1 (en) 2016-02-22
MX362807B (es) 2019-02-13
EP2995298B1 (en) 2021-06-23
ES2890523T3 (es) 2022-01-20
WO2014182093A1 (ko) 2014-11-13
US20160120867A1 (en) 2016-05-05
BR112015028124A2 (pt) 2017-07-25
CN105451717B (zh) 2018-05-22
BR112015028124B1 (pt) 2023-02-28
EP2995298A1 (en) 2016-03-16
US9629844B2 (en) 2017-04-25
MX2015015356A (es) 2016-03-04
KR20140132621A (ko) 2014-11-18
JP2016518404A (ja) 2016-06-23
KR101485243B1 (ko) 2015-01-21
CN105451717A (zh) 2016-03-30
HK1218076A1 (zh) 2017-02-03
RU2636783C2 (ru) 2017-11-28
JP6159879B2 (ja) 2017-07-05
EP2995298A4 (en) 2017-01-25
PH12015502542A1 (en) 2016-02-22
RU2015149114A (ru) 2017-06-09

Similar Documents

Publication Publication Date Title
CL2015003266A1 (es) Formulación estabilizada de pemetrexed.
PH12017501324B1 (en) Vapour provision system and cartridge therefor
MX2015005238A (es) Unidad de empaque de un producto farmacuetico, medico o cosmetico y un metodo de esterilizacion de un producto farmaceutico, medico o cosmetico que se puede colocar en la unidad de empaque.
PH12017500155A1 (en) Aerosol provision system
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
MX2015017821A (es) Heterociclos bi-o triciclicos activos como plaguicidas con sustituyentes que contienen azufre.
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
CL2015002786A1 (es) Aparato para dosis medida de sustancia de control del olor
AR098168A1 (es) Formulación estable de insulina glulisina
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
TWD164234S (zh) 香水瓶
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
MX2022000915A (es) Metodo para prolongar la viabilidad de esporas fungicas en formulaciones liquidas.
CL2017001186A1 (es) Comprimido multicapa que contiene un fármaco inestable a la luz
MX2016003512A (es) Recipiente para crioconservacion.
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
PH12015501602A1 (en) Agent for elevating nitric oxide concentration
SG10201709595WA (en) Solutions for increasing the stability and shelf life of an organ and tissue preservation solution
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
AR111032A1 (es) Composición líquida que contiene pradofloxacina
UA99206U (uk) Сплав для зберігання водню
CR20140278A (es) Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales
PE20151597A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
UA88697U (uk) Спосіб фіброезофагогастроскопії у дітей, хворих на активну форму туберкульозу